Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory

Journal of Clinical Microbiology

Volumn 51, Issue 3, 2013, Pages 880-886

  Avidor, Boaz ^a,b   Girshengorn, Shirley ^a,b   Matus, Natalia ^a,b   Talio, Hadass ^a,b   Achsanov, Svetlana ^a,b   Zeldis, Irene ^a,b   Fratty, Ilana S ^a,b   Katchman, Eugene ^b,c   Brosh Nissimov, Tal ^b,c   Hassin, David ^b,d   Alon, Danny ^b,e   Bentwich, Zvi ^b   Yust, Israel ^b   Amit, Sharon ^b,c   Forer, Relly ^f   Shultsman, Ina Vulih ^f,g   Turnerb, Dan ^b,c  

^a Laboratory for Viruses and Molecular Biology   (Israel)

^b Crusaid Kobler AIDS Center   (Israel)

^c Infectious Disease Unit   (Israel)

^d Department of Internal Medicine ^*  (Israel)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f RABIN MEDICAL CENTER   (Israel)

^g Dyn Diagnostics   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING;

ADULT; AGED; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTANT PROTEINS; MUTATION, MISSENSE; VIRAL PROTEINS; VIROLOGY; YOUNG ADULT;

EID: 84874069503     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02652-12     Document Type: Article

References (28)

1. Dunn DT, Coughlin K, Cane PA. 2011. Genotypic resistance testing in routine clinical care. Curr. Opin. HIV AIDS 6:251-257.
2. Sen S, Tripathy SP, Paranjape RS. 2006. Antiretroviral drug resistance testing. J. Prostgrad. Med. 52:187-193.
3. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Faloon J, Davey RT, Jr, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM. 2005. Multiple linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43:406-413.
4. Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, Mclyntyre J, Mellors J, Morris L, Coffin J. 2006. Persistence of nevirapine-resistance HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV transmission. Proc. Natl. Acad. Sci. U. S. A. 103: 7094-7099.
5. Shafer RW. 2009. Low-abundance drug-resistance HIV-1 variants: finding significance in an Era of abundant diagnostic and therapeutic options. J. Infect. Dis. 199:610-612.
6. Lecossier D, Shulman NS, Moran-Joubert L, Shafer RW, Joly V, Zolopa AR, Clavel F, Hance AJ. 2005. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J. Acquir. Defic. Syndr. 38:37- 42.
7. Johnson JA, Li Morris J-FL, Martinon N, Gray G, Mclntyre J, Heneine W. 2005. Emergence of drug-resistant HIV-1 after Intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192:16 -23.
8. Metzner KJ, Giulier SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, Gunthard HF, Cavassini M. 2009. Minority quasispecies of drugresistance HIV-1 that lead to early therapy failure in treatment-naive and adherent patients. Clin. Infect. Dis. 48:239 -247.
9. Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin M, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S, Ziermann R, Zhao RY, Jennings CL, Brenner J, Brambilla D, Mellors JW. 2006. Blinded multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 44:2612-2614.
10. Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, Mwatha A, Guay LA, Mmiro F, Musoke P, Kumwenda N, Taha TE, Jackson B, Eshelman SH. 2006. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J. Acquir. Immune Defic. Syndr. 42:610- 613.
11. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Bera J, Braverman MS, Chen YJ, Dewell SB, Du L, Fierro JM, Gomes XV, Godwin BC, He W, Helgesen S, Ho CH, Irzyk GP, Jando SC, Alenquer ML, Jarvie TP, Jirage KB, Kim JB, Knight JR, Lanza JR, Leamon JH, Lefkowitz SM, Lei M, Li J, Lohman KL, Lu H, Makhijani VB, McDade KE, MaKenna MP, Myers EW, Nickerson E, Nobile JR, Plant R, Puc BP, Ronan MT, Roth GT, Sarkis GJ, Simons JF, Simpson JW, Srinivasan M, Tartaro KR, Tomasz A, Vogt KA, Volkmer GA, Wang SH, Wang Y, Weiner MP, Yu P, Begley RF, Rothenberg JM. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376 -380.
12. Barzon L, Lavezzo E, Militello V, Toppo S, Palu' G. 2011. Applications of next-generation sequencing technologies to diagnostic virology. Int. J., Mol. Sci. 12:7861-7884.
13. Eriksson N, Pachter L, Mitsuya Y, Rhee Wang S-YC, Gharizadeh B, Ronaghi M, Shafer RW, Beerenwinkel N. 2008. Viral population estimation using pyrosequencing. PLoS One 4:e1000074. doi:10.1371/journal .pcbi.1000074.
14. Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, Leitner T, Lundeberg J, Andersson B, Albert J. 2010. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5:e11345. doi:10.1371/journal.pone.0011345.
15. Messiaen P, Verhofstese C, Vandenbroucke I, Dinakis S, Van Eygen V, Thys K, Winters B, Aerssens J, Vogelaers D, Stuyver LJ, Vandekkerckhove L. 2012. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology 426:7-11.
16. Delobel P, Saiiou A, Nicot F, Dubois M, Trancart S, Tangre P, Aboulker J-PTaburet A-MMolina Massip J-MP, Marchou B, Izopet J. 2011. Minor HIV-1 variants with K103N resistance mutation during intermittent efavirenz- containing antiretroviral therapy and virological failure. PLoS One 6:e21655. doi:10.1371/journal.pone.0021655.
17. Dudley DW, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, Costa PR, Sauer MM, Kallas EG, O'connor DH. 2012. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 7:e36494. doi:10.1371/journal.pone.0036494.
18. Simen BB, Simons JF, Hullseik KH, Novak RM, MacArthur RD, Baxter JD, Hunag CL, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothenberg JM, Egholm M, Kozal MJ, Terry Beirin Community Programs for Clinical Research on AIDS. 2009. Low-abundance drugresistant viral variants in chronically HIV-infected antiretroviral treatment- naive patients significantly impact treatment outcomes. J. Infect. Dis. 199:693-701.
19. Recordon-Pinson P, Papuchon J, Reigadas S, Deshpande A, Fleury H. 2012. K65R in subtype C HIV isolates from patients falling on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequence data. PLoS One 7:e36549. doi:10.1371/journal.pone.0036549.
20. Borras E, Juardo I, Hernan I, Jose M, Garmundi MJ, Dias M, Marti I, Mane B, Arcusa A, Agundez AGJ, Blanca M, Carballo M. 2011. Clinical pharmacogenic testing of KRAS, BRAF, and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 11:406-415. doi:10.1186/1471-2407-11- 406.
21. Johnson VA, Galvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011. Update of drug resistance mutations in HIV-1. Top. Antiviral Med. 19:156 -164.
22. Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, Dieckhaus K, Rosen MI, Kozal M. 2009. Low-abundance HIV drugresistance viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 4:e6079. doi:10.1371/journal.pone .0006079.
23. Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, Murell B, Scheffler K, Smith D. 2012. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J. Virol. 86:6231- 6237.
24. Saskova KG, Koziseq M, Rezakova P, Brynda J, Yashina T, Kagan RM, Konvalinka J. 2009. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J. Virol. 83:8810-8818.
25. Roquebert B, Malet I, Wirden M, Tubiana R, Valantin A, Simon A, Katlama C, Peytavin G, Calvez V, Marcellin AG. 2006. Role of HIV-1 minority populations on resistance mutational Pattern evolution and susceptibility to protease inhibitors. AIDS 20:287-289.
26. Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St John E, Moreno E, Kozal M. 2012. Virologic failures on initial boosted-PI regimen infrequently posses low-level variants with major PI resistance mutations by ultra-deep sequencing. PLoS One 7:e30118. doi: 10.1371/journal. pone.0030118.
27. Varghese V, Wang E, Babrzadeh F, Bachman MH, Shahriar R, Liu T, Mappala SJM, Gharizadeh B, Fessel WJ, Katzenstein D, Kassaye S, Shafer RW. 2010. Nucleic acid template and the risk of a PCR-induced HIV-1 drug-resistance mutation. PLoS One 5:e10992. doi:10.1371 /journal.pone.0010992.
28. Jiang Q, Turner T, Sosa MX, Rakha A, Arnold S, Chakravarti A. 2012. Rapid efficient human mutation detection using a benchtop nextgeneration DNA sequencer. Hum. Mutat. 33:281-289.